|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
FY2018
12 months to Dec 31, 2018
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Contract revenue from Healios | |||||
| Healios | |||||
| Royalty and other contract revenue | |||||
| Total contract revenue from Healios | |||||
| Grant revenue | |||||
| Total revenues | |||||
| Costs and expenses | |||||
| Research and development (including stock compensation expense of $3,037, $3,642 and $3,351 in 2022, 2021 and 2020, respectively) | |||||
| General and administrative (including stock compensation expense of $3,166, $4,914 and $4,028 in 2022, 2021 and 2020, respectively) | |||||
| Depreciation | |||||
| Total costs and expenses | |||||
| Gain from insurance proceeds, net | |||||
| Loss from operations | |||||
| Income from change in fair value of warrants, net | |||||
| Other income (expense), net | |||||
| Net loss | |||||
| Comprehensive loss | |||||
| Net loss per common share, basic and diluted (in dollars per share) | |||||
| Weighted average shares outstanding, basic and diluted (in shares) | |||||
| Net loss per common share, basic (in dollars per share) | |||||
| Net loss per common share, diluted (in dollars per share) | |||||
| Weighted average shares outstanding, basic (in shares) | |||||
| Weighted average shares outstanding, diluted (in shares) | |||||
Loading...
